Rapha Capital BioVentures Fund I

About

Portfolio · 1

FIZE Medical

FIZE Medical develops an AI-powered fluid management platform for critically ill patients, providing real-time urine output monitoring and early detection of acute kidney injury.

2 rounds $9.3M committed Latest: 2021-12

Q&A

What is the primary focus of Rapha Capital BioVentures Fund I?

Rapha Capital BioVentures Fund I focuses on early-stage life science companies, typically leading Series A financings, with an emphasis on transformative products, technologies, or processes in medicine, healthcare, and biotechnology.

When was Rapha Capital BioVentures Fund I founded?

Rapha Capital BioVentures Fund I was founded in April 2021.

What is the total AUM for Rapha Capital BioVentures Fund I?

Rapha Capital BioVentures Fund I has a total AUM of $100,000,000.

Which fund has Rapha Capital BioVentures Fund I raised?

Rapha Capital BioVentures Fund I, LP was raised in 2021 with a size of $100,000,000.

What investment stages does Rapha Capital BioVentures Fund I target?

Rapha Capital BioVentures Fund I targets Pre-Seed, Seed, and Series A investment stages.

What are the preferred sectors for investment by Rapha Capital BioVentures Fund I?

Rapha Capital BioVentures Fund I's preferred sector for investment is Health Tech & Life Sciences.

In which geographies does Rapha Capital BioVentures Fund I prefer to invest?

Rapha Capital BioVentures Fund I prefers to invest in the United States and Israel.

Who is a key executive at Rapha Capital BioVentures Fund I?

Kevin Slawin is the Founder and Managing Partner at Rapha Capital BioVentures Fund I.